RxDoctor Payments Data

Alexandra Battalora

Gerontology · Hammond, LANPI 1437931508

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,959 of the $2,336 with a category attached, or 83.8%. 15 manufacturers reported payments, led by Boston Scientific at 38.6% of the total.

$2,336in general payments, 2019–2025

Across 55 payments — averaging $42.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$902
  • Abiomed$345
  • Kestra Medical Technology Services, Inc.$315
  • Edwards Lifesciences$168
  • Penumbra, Inc.$140
  • Abbott$132
  • plus $334 from 9 others

What the payments were for

  • Travel & lodging$37716%
  • Food & beverage$1,95984%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,336 in reported general payments places this provider in the 75th percentile of 64 gerontology providers in Louisiana.

See all gerontology providers in Louisiana

Medicare billing

Part B allowed, 2024
$19,278
Medicare patients
159
Services billed
256

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin42$27,631
EntrestoSacubitril/Valsartan30$27,543
EliquisApixaban36$23,657
BrilintaTicagrelor46$22,756
FarxigaDapagliflozin Propanediol11$7,162
XareltoRivaroxaban13$7,106
Ranolazine ErRanolazine26$1,158
Metoprolol Succinate88$968
Midodrine Hcl14$659
ClopidogrelClopidogrel Bisulfate75$406
Telmisartan12$261
Carvedilol24$200
Amiodarone Hcl27$170
Atorvastatin Calcium33$166
Isosorbide Mononitrate ErIsosorbide Mononitrate34$163

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta, Farxiga$14$29,91857 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 64 gerontology providers in Louisiana.

Other gerontology in Hammond

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →